Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...

In a new paper in Nature, a team of researchers from JPMorganChase, Quantinuum, Argonne National Laboratory, Oak Ridge ...

Milestone Pharmaceuticals hit another bump in the road in its quest to get Cardamyst approved for paroxysmal supraventricular ...

The Food and Drug Administration has turned away a proposed nasal spray from Milestone Pharmaceuticals to treat a type of irregular heartbeat over concerns about how the drug is manufactured.

Quantum computers hold the potential to be orders of magnitude more powerful than the world’s best supercomputers by ...

Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...

(RTTNews) - Milestone Pharmaceuticals (MIST) announced the FDA issued a Complete Response Letter regarding its New Drug Application for CARDAMYST nasal spray, a prescription medication in ...

MONTREAL and CHARLOTTE, N.C. - Milestone Pharmaceuticals Inc. (Nasdaq ... in response to the company’s New Drug Application (NDA) for CARDAMYST™ (etripamil) nasal spray.

Mecademic, a pioneer in ultra-compact, high-precision robotic solutions, has announced a major milestone: 15% of all robots shipped in the past 12 months have been deployed in optics and photonics ...